Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic ...
Asciminib, a BCR::ABL1 inhibitor targeting the ABL myristoyl pocket, shows efficacy against CML-CP, including T315I mutation, with 40 mg b.i.d. and 200 mg b.i.d. dosing regimens. An 80 mg q.d. regimen is proposed for improved patient compliance, supported by model-informed drug development, demonstrating similar efficacy and safety profiles to 40 mg b.i.d.
Related Clinical Trials
Highlighted Terms
Related News
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic ...
Asciminib, a BCR::ABL1 inhibitor targeting the ABL myristoyl pocket, shows efficacy against CML-CP, including T315I mutation, with 40 mg b.i.d. and 200 mg b.i.d. dosing regimens. An 80 mg q.d. regimen is proposed for improved patient compliance, supported by model-informed drug development, demonstrating similar efficacy and safety profiles to 40 mg b.i.d.